We offer a discovery service to academia, government and industry through the Serimmune universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify antigens and epitopes associated with many diseases - all in a single assay.

Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next-generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Through this, we gain a broad view of an individual’s environmental exposures and the unique immune responses to these exposures in disease and health.

Serimmune was founded on the belief that the information coded in the individual’s functional antibody repertoire is key to understanding human disease. To fulfill this vision, we created a technology for building and interpreting a dynamic map of human immunity which continually evolves to map interactions between functional antibody repertoire and human disease. Linkages between antibody response to pathogens have been shown in oncology, autoimmune, infectious, neurodegenerative, and other complex diseases.